Hennepin County commissioners mull taking over HCMC in effort to keep hospital open
Hennepin County Medical Center (HCMC) takes patients who don't have insurance. Officials believe it has caused an annual debt of tens of millions of dollars.
Even though HCMC is considered a county hospital, it has been run by the medical care group Hennepin Healthcare. HCMC's workers work for Hennepin Healthcare. Over the last couple of years, a group of appointed business and medical community volunteers have been overseeing the budget they admit is tricky.
"We are facing a structural financial crisis at this hospital because we take care of patients who don't have insurance or are underinsured," said Mohamed Omar, chief operations officer and board chair. "That is why this hospital is in financial trouble, it's not because of mismanagement."
But some county commissioners have questions and want to take back financial oversight. They are the ones who pay for the deficit.
WCCO obtained data showing the hospital had $38 million in debt last year, which was picked up by property taxes.
Commissioner Jeffrey Lunde is voting yes to taking back control. He says the deficit could mean raising property taxes to help cover the deficit.
"Our commitment is to keep that hospital open, but there needs to be changing," said Lunde. "I think what you are seeing by the board, saying that we need to step in, we've hit the moment that it is the final buck."
Dozens at the committee meeting backed that idea, including a Hennepin Healthcare nurse who believes the path they are on is not working and they need redirection.
The committee voted to push the change to a final vote that they say will help the system.
Lunde says if the change goes through on Aug. 12, HCMC will continue to accept patients without insurance.
Hashtags
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
CBS News
4 minutes ago
- CBS News
Minnesota sees sedative overdose spike: "Naloxone isn't going to help"
By WCCO reporter Ashley Grams The Minnesota Department of Health issued a health advisory last week warning of an increase in overdose cases involving sedatives. Data collected by the department's Minnesota Drug Overdose and Substance Use Surveillance Activity (MNDOSA) project shows just one overdose case where the sedative xylazine was detected. That number jumped to 53 in 2024. Now, the state is tracking another sedative emerging in the drug supply. "Medetomidine, it has been seen in other parts of the country," said Deepa McGriff, the department's epidemiologist supervisor. "It is a veterinary sedative that's not approved for human use, and in 2025 we started to see more detections." The state's Public Health Laboratory started tracking medetomidine in 2024 and this year has seen 12 cases. "Here in Minnesota, we are somewhat insulated, initially, from new substances as they emerge, maybe on the East Coast or West Coast," said Jason Peterson, who supervises the chemical threats and bio monitoring units at the Public Health Laboratory. Peterson says medetomidine was "starting to grow" out on the East Coast. "They do take delays in a lot of times in entering our state, but we are mindful of that and we are mindful of the patterns where drugs typically flow across the country," he said. This increase in sedatives is a dangerous reality for drug users across the state. "Certainly for the subset of people that we work with that are using substances, we do see these things come through," said John Tribbett, the service area director for Avivo's ending homelessness division. "We are at a point unfortunately where you never know what people are getting, and what they end up putting in their body. Tribbett said all of Avivo's teams are trained in overdose reversal. The state's health advisory warns that these sedatives "significantly complicates the treatment of overdose patients." McGriff says the department wants the community and first responders to understand that sedatives may be a factor in an overdose, and how that can impact treatment. "If there's a sedative involved, the Naloxone isn't going to work to reverse that unresponsiveness," McGriff said. "We want to emphasize the need to focus on restoring the breathing of the overdose patients, rather than restoring the consciousness." McGriff said an opioid reversal drug like naloxone should still be used in these cases. Tribbett believes the emergence of medetomidine is a reflection of policy aimed at restricting xylazine. "What we see time and time again is a crackdown on one particular chemical, and then something emerges to replace it," Tribbett said. Some states have made an effort to limit access to xylazine in recent years, including Pennsylvania, which classified xylazine as a Schedule 3 drug. Minnesota's health department says data is still limited when it comes to medetomidine, but awareness is important — something Tribbett agrees with. "Making people aware, helping our teams have the information they need, helping people in the community know what's out there," Tribbett said.
Forbes
34 minutes ago
- Forbes
Gaza Humanitarian Crisis Is At 'Point Of No Return'— Here's What US Needs To Do: Oxfam America CEO
There has been international outrage over the humanitarian crisis in Gaza, as the war between Israel and Hamas has been going on for close to two years. The Integrated Food Security Phase Classification said that "the worst-case scenario of famine is currently playing out in the Gaza Strip" and there is 'mounting evidence shows that widespread starvation, malnutrition, and disease are driving a rise in hunger-related deaths.' President and CEO of Oxfam America Abby Maxman joined Brittany Lewis on "Forbes Newsroom" to discuss. Watch the full interview above.
Yahoo
an hour ago
- Yahoo
Tandem Diabetes (NASDAQ:TNDM) Exceeds Q2 Expectations But Stock Drops 17%
Diabetes technology company Tandem Diabetes Care (NASDAQ:TNDM) reported Q2 CY2025 results topping the market's revenue expectations , with sales up 8.5% year on year to $240.7 million. The company expects the full year's revenue to be around $1 billion, close to analysts' estimates. Its GAAP loss of $0.78 per share was significantly below analysts' consensus estimates. Is now the time to buy Tandem Diabetes? Find out in our full research report. Tandem Diabetes (TNDM) Q2 CY2025 Highlights: Revenue: $240.7 million vs analyst estimates of $237.1 million (8.5% year-on-year growth, 1.5% beat) EPS (GAAP): -$0.78 vs analyst estimates of -$0.39 (significant miss) Adjusted EBITDA: -$1.85 million vs analyst estimates of $2.34 million (-0.8% margin, significant miss) The company reconfirmed its revenue guidance for the full year of $1 billion at the midpoint Operating Margin: -21.5%, down from -13.9% in the same quarter last year Sales Volumes rose 5% year on year, in line with the same quarter last year Market Capitalization: $1.01 billion Company Overview With technology that automatically adjusts insulin delivery based on continuous glucose monitoring data, Tandem Diabetes Care (NASDAQ:TNDM) develops and manufactures automated insulin delivery systems that help people with diabetes manage their blood glucose levels. Revenue Growth Examining a company's long-term performance can provide clues about its quality. Any business can have short-term success, but a top-tier one grows for years. Over the last five years, Tandem Diabetes grew its sales at an impressive 19.5% compounded annual growth rate. Its growth beat the average healthcare company and shows its offerings resonate with customers. We at StockStory place the most emphasis on long-term growth, but within healthcare, a half-decade historical view may miss recent innovations or disruptive industry trends. Tandem Diabetes's annualized revenue growth of 12.4% over the last two years is below its five-year trend, but we still think the results suggest healthy demand. Tandem Diabetes also reports its number of pump shipments, which reached 21,000 in the latest quarter. Over the last two years, Tandem Diabetes's pump shipments averaged 2.9% year-on-year growth. Because this number is lower than its revenue growth, we can see the company benefited from price increases. This quarter, Tandem Diabetes reported year-on-year revenue growth of 8.5%, and its $240.7 million of revenue exceeded Wall Street's estimates by 1.5%. Looking ahead, sell-side analysts expect revenue to grow 4.8% over the next 12 months, a deceleration versus the last two years. This projection is underwhelming and suggests its products and services will see some demand headwinds. Unless you've been living under a rock, it should be obvious by now that generative AI is going to have a huge impact on how large corporations do business. While Nvidia and AMD are trading close to all-time highs, we prefer a lesser-known (but still profitable) stock benefiting from the rise of AI. Click here to access our free report one of our favorites growth stories. Adjusted Operating Margin Adjusted operating margin is one of the best measures of profitability because it tells us how much money a company takes home after subtracting all core expenses, like marketing and R&D. It also removes various one-time costs to paint a better picture of normalized profits. Tandem Diabetes's high expenses have contributed to an average adjusted operating margin of negative 7.9% over the last five years. Unprofitable healthcare companies require extra attention because they could get caught swimming naked when the tide goes out. It's hard to trust that the business can endure a full cycle. Analyzing the trend in its profitability, Tandem Diabetes's adjusted operating margin decreased by 15.6 percentage points over the last five years. The company's two-year trajectory also shows it failed to get its profitability back to the peak as its margin fell by 1.6 percentage points. This performance was poor no matter how you look at it - it shows its expenses were rising and it couldn't pass those costs onto its customers. Tandem Diabetes's adjusted operating margin was negative 13.2% this quarter. Earnings Per Share Revenue trends explain a company's historical growth, but the long-term change in earnings per share (EPS) points to the profitability of that growth – for example, a company could inflate its sales through excessive spending on advertising and promotions. Tandem Diabetes's earnings losses deepened over the last five years as its EPS dropped 34.2% annually. We tend to steer our readers away from companies with falling EPS, where diminishing earnings could imply changing secular trends and preferences. If the tide turns unexpectedly, Tandem Diabetes's low margin of safety could leave its stock price susceptible to large downswings. In Q2, Tandem Diabetes reported EPS at negative $0.78, down from negative $0.47 in the same quarter last year. This print missed analysts' estimates. Over the next 12 months, Wall Street expects Tandem Diabetes to improve its earnings losses. Analysts forecast its full-year EPS of negative $3.09 will advance to negative $1.00. Key Takeaways from Tandem Diabetes's Q2 Results It was encouraging to see Tandem Diabetes beat analysts' revenue expectations this quarter. On the other hand, its EPS missed and its sales volume fell short of Wall Street's estimates. Overall, this was a softer quarter. The stock traded down 17% to $12 immediately after reporting. Tandem Diabetes may have had a tough quarter, but does that actually create an opportunity to invest right now? If you're making that decision, you should consider the bigger picture of valuation, business qualities, as well as the latest earnings. We cover that in our actionable full research report which you can read here, it's free. Inicia sesión para acceder a tu cartera de valores
